Cirrhosis - Revision history

Danbot: Move calculators to own section with header (visible in TOC), expanded, before External Links

2026-03-21T15:07:23Z

Move calculators to own section with header (visible in TOC), expanded, before External Links

@@ Line 157: / Line 157: @@
 *[[Special:MyLanguage/Ascites|Ascites]]
 ==External Links== <!--T:26-->
@@ Line 169: / Line 174: @@
 [[Category:GI]]
 </translate>

Danbot: Add Child-Pugh Score calculator (collapsible)

2026-03-21T13:43:54Z

Add Child-Pugh Score calculator (collapsible)

← Older revision		Revision as of 13:43, 21 March 2026
Line 174:		Line 174:
	<div class="mw-collapsible-content">		<div class="mw-collapsible-content">
	{{MELD_Calculator}}		{{MELD_Calculator}}
			</div>
			</div>

			<div class="mw-collapsible mw-collapsed" style="border:1px solid #aaa; padding:5px; margin-top:10px;">
			<div style="font-weight:bold;">📊 Child-Pugh Score Calculator [show]</div>
			<div class="mw-collapsible-content">
			{{Child_Pugh_Calculator}}
	</div>		</div>
	</div>		</div>

Danbot: Add MELD Score calculator (collapsible)

2026-03-21T13:43:42Z

Add MELD Score calculator (collapsible)

← Older revision		Revision as of 13:43, 21 March 2026
Line 169:		Line 169:
	[[Category:GI]]		[[Category:GI]]
	</translate>		</translate>

			<div class="mw-collapsible mw-collapsed" style="border:1px solid #aaa; padding:5px; margin-top:10px;">
			<div style="font-weight:bold;">📊 MELD Score Calculator [show]</div>
			<div class="mw-collapsible-content">
			{{MELD_Calculator}}
			</div>
			</div>

Ostermayer: Marked this version for translation

2026-01-07T12:31:18Z

Marked this version for translation

← Older revision		Revision as of 12:31, 7 January 2026
Line 2:		Line 2:
	<translate>		<translate>

	==Background==		==Background== <!--T:1-->

			<!--T:2-->
	*A generally irreversible fibrotic scarring of the liver parenchyma resulting in liver failure		*A generally irreversible fibrotic scarring of the liver parenchyma resulting in liver failure
	*The twelfth leading cause of death in men and women in 2013<ref>Heron M. Deaths: Leading Causes for 2013. Natl Vital Stat Rep 2016: 16;65(2):1-95.</ref>		*The twelfth leading cause of death in men and women in 2013<ref>Heron M. Deaths: Leading Causes for 2013. Natl Vital Stat Rep 2016: 16;65(2):1-95.</ref>


	===Causes===		===Causes=== <!--T:3-->

			<!--T:4-->
	*[[Special:MyLanguage/Hepatitis\|Hepatitis]] chronic B and C		*[[Special:MyLanguage/Hepatitis\|Hepatitis]] chronic B and C
	*Alcoholic liver disease		*Alcoholic liver disease
Line 26:		Line 28:


	==Clinical Features==		==Clinical Features== <!--T:5-->

			<!--T:6-->
	[[File:Jaundice08.jpg\|thumb\|Jaundice of the skin]]		[[File:Jaundice08.jpg\|thumb\|Jaundice of the skin]]
	[[File:SpiderAngioma.jpg\|thumb\|Spider angioma]]		[[File:SpiderAngioma.jpg\|thumb\|Spider angioma]]
Line 40:		Line 43:


	==Differential Diagnosis==		==Differential Diagnosis== <!--T:7-->

	</translate>		</translate>
Line 50:		Line 53:


	==Evaluation==		==Evaluation== <!--T:8-->

			<!--T:9-->
	[[File:Auscities.png\|thumb\|Ascites appearance on ultrasound]]		[[File:Auscities.png\|thumb\|Ascites appearance on ultrasound]]
	[[File:CirrhosisWithAscitesMark.png\|thumb\|Liver cirrhosis with ascites on CT]]		[[File:CirrhosisWithAscitesMark.png\|thumb\|Liver cirrhosis with ascites on CT]]

	===Workup===		===Workup=== <!--T:10-->

			<!--T:11-->
	*CBC		*CBC
	*Chem 7		*Chem 7
Line 65:		Line 70:


	===Diagnosis===		===Diagnosis=== <!--T:12-->


	==Management==		==Management== <!--T:13-->

			<!--T:14-->
	'''Complications of cirrhosis'''		'''Complications of cirrhosis'''
	*[[Special:MyLanguage/Ascites\|Ascites]]		*[[Special:MyLanguage/Ascites\|Ascites]]
Line 80:		Line 86:
	*[[Special:MyLanguage/Hepatocellular carcinoma\|Hepatocellular carcinoma]]		*[[Special:MyLanguage/Hepatocellular carcinoma\|Hepatocellular carcinoma]]

			<!--T:15-->
	'''Pain management in cirrhotic patients'''		'''Pain management in cirrhotic patients'''
	*[[Special:MyLanguage/Acetaminophen\|Acetaminophen]] is safe for short-term use at reduced dose of 2 grams total per day		*[[Special:MyLanguage/Acetaminophen\|Acetaminophen]] is safe for short-term use at reduced dose of 2 grams total per day
Line 89:		Line 96:


	==Disposition==		==Disposition== <!--T:16-->

			<!--T:17-->
	*Often complex and should be based on presence/absence of acute complications		*Often complex and should be based on presence/absence of acute complications
	*If no complications present, discussion with patient's primary care provider or gastroenterologist recommended		*If no complications present, discussion with patient's primary care provider or gastroenterologist recommended


	==Prognosis==		==Prognosis== <!--T:18-->


	===Child-Pugh Score[http://www.mdcalc.com/child-pugh-score-for-cirrhosis-mortality/ <ref>Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Edited by CG Child. Philadelphia: Saunders 1964:50-64</ref>]===		===Child-Pugh Score[http://www.mdcalc.com/child-pugh-score-for-cirrhosis-mortality/ <ref>Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Edited by CG Child. Philadelphia: Saunders 1964:50-64</ref>]=== <!--T:19-->

			<!--T:20-->
	{\| class="wikitable"		{\| class="wikitable"
	\|-		\|-
Line 115:		Line 124:
	\|}		\|}

			<!--T:21-->
	*Score ≤ 7 = Class A = 100% and 85% one and two-year patient survival		*Score ≤ 7 = Class A = 100% and 85% one and two-year patient survival
	*Score 7 - 9 = Class B = 80% and 60% one and two-year patient survival		*Score 7 - 9 = Class B = 80% and 60% one and two-year patient survival
Line 120:		Line 130:


	===MELD Score[http://www.mdcalc.com/meld-score-model-for-end-stage-liver-disease-12-and-older/ <ref>Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001 Feb;33(2):464-70.</ref>]===		===MELD Score[http://www.mdcalc.com/meld-score-model-for-end-stage-liver-disease-12-and-older/ <ref>Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001 Feb;33(2):464-70.</ref>]=== <!--T:22-->

			<!--T:23-->
	{\| class="wikitable"		{\| class="wikitable"
	\|-		\|-
Line 138:		Line 149:


	==See Also==		==See Also== <!--T:24-->

			<!--T:25-->
	*[[Special:MyLanguage/Viral hepatitis\|Viral hepatitis]]		*[[Special:MyLanguage/Viral hepatitis\|Viral hepatitis]]
	*[[Special:MyLanguage/Acute hepatic failure\|Acute hepatic failure]]		*[[Special:MyLanguage/Acute hepatic failure\|Acute hepatic failure]]
Line 146:		Line 158:


	==External Links==		==External Links== <!--T:26-->


	==References==		==References== <!--T:27-->

			<!--T:28-->
	<references/>		<references/>

			<!--T:29-->
	[[Category:GI]]		[[Category:GI]]
	</translate>		</translate>

Ostermayer: Prepared the page for translation

2026-01-04T21:48:49Z

Prepared the page for translation

Show changes

Rossdonaldson1: /* Prognosis */

2024-02-28T22:29:09Z

Prognosis

← Older revision		Revision as of 22:29, 28 February 2024
Line 70:		Line 70:

	==Prognosis==		==Prognosis==

	===Child-Pugh Score[http://www.mdcalc.com/child-pugh-score-for-cirrhosis-mortality/ <ref>Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Edited by CG Child. Philadelphia: Saunders 1964:50-64</ref>]===		===Child-Pugh Score[http://www.mdcalc.com/child-pugh-score-for-cirrhosis-mortality/ <ref>Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Edited by CG Child. Philadelphia: Saunders 1964:50-64</ref>]===
	{\| class="wikitable"		{\| class="wikitable"
Line 90:		Line 89:
	*Score 7 - 9 = Class B = 80% and 60% one and two-year patient survival		*Score 7 - 9 = Class B = 80% and 60% one and two-year patient survival
	*Score ≥ 10 = Class c = 45% and 35% one and two-year patient survival		*Score ≥ 10 = Class c = 45% and 35% one and two-year patient survival
	~~<br />~~
	===MELD Score[http://www.mdcalc.com/meld-score-model-for-end-stage-liver-disease-12-and-older/ <ref>Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001 Feb;33(2):464-70.</ref>]===		===MELD Score[http://www.mdcalc.com/meld-score-model-for-end-stage-liver-disease-12-and-older/ <ref>Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001 Feb;33(2):464-70.</ref>]===
	{\| class="wikitable"		{\| class="wikitable"

Rossdonaldson1: /* Sites of Portalcaval Anastomosis */

2024-02-28T22:27:16Z

Sites of Portalcaval Anastomosis

@@ Line 15: / Line 15: @@
 *[[Cystic Fibrosis]]
-===Sites of Portalcaval Anastomosis ===
+{{Sites of Portalcaval Anastomosis}}
 ==Clinical Features==

Rossdonaldson1: /* Sites of Portalcaval Anastomosis */

2024-02-28T22:26:43Z

Sites of Portalcaval Anastomosis

← Older revision		Revision as of 22:26, 28 February 2024
Line 30:		Line 30:
	\|-		\|-
	\|(no clinical name)		\|(no clinical name)
	\|Right colic vein, middle colic vein, left colic vein \|Right colic vein, middle colic vein, left colic vein\| Retroperitoneal veins of Retzius		\|Right colic vein, middle colic vein, left colic vein \|Right colic vein, middle colic vein, left colic vein\|\| Retroperitoneal veins of Retzius
	\|-		\|-
	\| rowspan="2" \|Intrahepatic \|\|Hepatic pseudolesions \|\|Perihepatic veins of Sappey \|\|Superior epigastric vein		\| rowspan="2" \|Intrahepatic \|\|Hepatic pseudolesions \|\|Perihepatic veins of Sappey \|\|Superior epigastric vein

Rossdonaldson1: /* Sites of Portalcaval Anastomosis */

2024-02-28T22:26:21Z

Sites of Portalcaval Anastomosis

← Older revision		Revision as of 22:26, 28 February 2024
Line 30:		Line 30:
	\|-		\|-
	\|(no clinical name)		\|(no clinical name)
	\|Right colic vein, middle colic vein, left colic vein \|Retroperitoneal veins of Retzius		\|Right colic vein, middle colic vein, left colic vein \|Right colic vein, middle colic vein, left colic vein\| Retroperitoneal veins of Retzius
	\|-		\|-
	\| rowspan="2" \|Intrahepatic \|\|Hepatic pseudolesions \|\|Perihepatic veins of Sappey \|\|Superior epigastric vein		\| rowspan="2" \|Intrahepatic \|\|Hepatic pseudolesions \|\|Perihepatic veins of Sappey \|\|Superior epigastric vein

Rossdonaldson1: /* Sites of Portalcaval Anastomosis */

2024-02-28T22:25:17Z

Sites of Portalcaval Anastomosis

← Older revision		Revision as of 22:25, 28 February 2024
Line 32:		Line 32:
	\|Right colic vein, middle colic vein, left colic vein \|Retroperitoneal veins of Retzius		\|Right colic vein, middle colic vein, left colic vein \|Retroperitoneal veins of Retzius
	\|-		\|-
	\| rowspan="2" \|Intrahepatic \|Hepatic pseudolesions \|~~[http://radiopaedia.org/articles/veins-of-sappey-1~~ Perihepatic veins of Sappey] \|Superior epigastric vein		\| rowspan="2" \|Intrahepatic \|\|Hepatic pseudolesions \|\|Perihepatic veins of Sappey \|\|Superior epigastric vein
	\|-		\|-
	\| Patent ductus venosus \|\| Left branch of portal vein \|\| Inferior vena cava		\| Patent ductus venosus \|\| Left branch of portal vein \|\| Inferior vena cava